has entered an exclusive global licensing agreement with Foreseen Biotechnology for FS001, a potentially first-in-class antibody-drug conjugate (ADC). This partnership grants Ipsen worldwide rights to develop, manufacture and commercialise FS001, which is in the final stages of its pre-clinical phase. FS001 targets a novel tumour-associated antigen prevalent in many solid tumours, critical for their growth and spread.
The gold standard of business intelligence. FS001 incorporates a stable and cleavable linker with a potent topoisomerase I inhibitor. Preclinical studies have shown FS001 to be effective in multi-drug-resistant cancer models.
Foreseen Biotechnology is eligible to receive $1.03bn in payments, including upfront, development, regulatory and commercial milestones, as well as tiered royalties on global sales, based upon successful development and regulatory approvals. Ipsen senior vice-president and head of early development Mary Jane Hinrichs stated: “We are excited to add FS001, the second ADC Ipsen has in-licensed this year, to our growing pipeline.
Using cutting-edge proteomics technology and AI-powered screening platforms the Foreseen team has uncovered a novel and clinically relevant target which could unlock the potential of ADCs for even more people living with hard-to-treat forms of cancer. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shor.
